Table 2 General patient characteristics
From: Tailored immunosuppression after kidney transplantation - a single center real-life experience
Parameter | All patients (n = 204) | No DSAa (n = 169) | With DSAb (n = 35) | P-value |
|---|---|---|---|---|
Recipient age (year), mean (SD) | 51 (±13) | 51 (±12) | 49 (±14) | 0.428 |
Female sex, n (%) | 83 (40.7) | 63 (37.3) | 20 (57.1) | 0.024 |
Primary renal disease, n (%) | 0.517 | |||
Vascular/hypertensive | 18 (8.8) | 15 (8.9) | 3 (8.6) | |
Diabetic | 36 (17.6) | 33 (19.5) | 3 (8.6) | |
Glomerulonephritis/vasculitis | 61 (29.9) | 45 (26.6) | 16 (45.7) | |
Cystic | 31 (15.2) | 26 (15.4) | 5 (14.3) | |
Urological | 17 (8.3) | 14 (8.3) | 3 (8.6) | |
Tubulointerstitiell | 9 (4.4) | 7 (4.1) | 2 (5.7) | |
HUS/TTP | 1 (0.5) | 1 (0.6) | 0 (0.0) | |
Others | 8 (3.9) | 7 (4.1) | 1 (2.9) | |
Indefinite | 23 (11.3) | 21 (12.4) | 2 (5.7) | |
Dialysis, n (%) | 173 (84.8) | 141 (83.4) | 32 (91.4) | 0.175 |
Number of transplantation, n (%) | < 0.001 | |||
First | 172 (84.3) | 154 (91.1) | 18 (51.4) | |
Second | 30 (14.7) | 15 (8.9) | 15 (42.9) | |
Third | 2 (1.0) | 0 (0.0) | 2 (5.7) | |
Donor type, n (%) | 0.547 | |||
Living | 69 (33.8) | 57 (33.7) | 12 (34.3) | |
Deceased | 135 (66.2) | 112 (66.3) | 23 (65.7) | |
Type of transplantation, n (%) | 0.195 | |||
Kidney | 180 (88.2) | 146 (86.4) | 34 (97.1) | |
Kidney + pancreas | 21 (10.3) | 20 (11.8) | 1 (2.9) | |
Kidney + pancreatic islets | 3 (1.5) | 3 (1.8) | 0 (0.0) | |
Blood group incompatibility, n (%) | 14 (6.9) | 11 (6.5) | 3 (8.6) | 0.443 |
HLA mismatches, mean (SD) | 4.6 (±1.9) | 4.5 (±1.9) | 5.2 (±1.8) | 0.228 |
Induction treatment, n (%) | ||||
Thymoglobulin | 47 (23.0) | 22 (13.0) | 25 (71.4) | < 0.001 |
Basiliximab | 46 (22.5) | 41 (24.3) | 5 (14.3) | 0.143 |
Rituximab (overall) | 11 (5.4) | 7 (4.1) | 4 (11.4) | 0.098 |
Rituximab alone | 7 (3.4) | |||
Rituximab and basiliximab | 3 (1.5) | |||
Rituximab and thymoglobulin | 1 (0.5) | |||
Maintenance immunosuppression, n (%) | ||||
Cyclosporine A | 96 (47.1) | 94 (55.6) | 2 (5.7) | < 0.001 |
Tacrolimus | 103 (50.5) | 70 (41.4) | 33 (94.3) | < 0.001 |